26 May 2013
Keywords: repligen, usa-based, corp, says, data, preclinical, study
Article | 22 September 2008
USA-based Repligen Corp says data from a preclinical study demonstrate
that its novel histone deacetylase inhibitor improved disease symptoms
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
22 September 2008
24 May 2013
© 2013 thepharmaletter.com